Get started
Author

Paul Casabianca

Observed names: Casabianca, Paul, P Casabianca, P. Casabianca
ORCID: 0009-0001-9980-5807
Observed ORCID: 0009-0001-9980-5807
OpenAlex ID: A5014222589
Epidemiology, patient management, and survival outcomes in resected patients with non-metastatic non-small cell lung cancer: a nationwide real-world study
2025 · Stéphane Renaud, Paul Casabianca, et al. · BMC Cancer · 9
PDF
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
2024 · Paul Casabianca, Marc Massetti, et al. · PharmacoEconomics - Open · 3
PDF
EE520 Hospital Costs in Resected Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC): A French Real-World Retrospective Study Based on the National Hospitalization Database (PMSI)
2023 · S. Renaud, A. Brouquet, et al. · Value in Health · 1
PDF
EE31 A Review of Indirect Costs Within Economic Appraisals in France
2025 · Romane Gerrer-Soustiel, Paul Casabianca, et al. · Value in Health
EPH148 Insights From a French Postmarketing Authorization Early Access (MA EA) Mechanism: Projecting Clinical and Economic Benefits of Neoadjuvant Nivolumab–Platinum-Based Chemotherapy (PDC) in Resectable Non-Small Cell Lung Cancer
2025 · Paul Casabianca, Jérémy CARETTE, et al. · Value in Health
EE10 A Cost-Effectiveness Analysis of First-Line Therapies for Microsatellite-Instability-High (MSI-H) or Mismatch-Repair-Deficient (dMMR) Unresectable or Metastatic Colorectal Cancer (mCRC) in France
2025 · Paul Casabianca, Romain Cohen, et al. · Value in Health
Analyse médicoéconomique de nivolumab + CT néoadjuvante dans le CBNPC exprimant PDL1 ≥ 1 % en France : une stratégie moins coûteuse et plus efficace que la CT néoadjuvante
2025 · P. Casabianca, J. Carette, et al. · Revue des Maladies Respiratoires Actualités
EE137 Cost-Effectiveness Analysis of Neoadjuvant Nivolumab Plus Platinum-Based Chemotherapy (PDC) in Resectable Non-Small Cell Lung Cancer (NSCLC) in France: A Situation of Dominance
2024 · P Casabianca, J Carette, et al. · Value in Health
PDF
EE511 Systematic Review of Cost Effectiveness Assessment Reports of Immune Checkpoint Inhibitors in Early and Advanced/Metastatic Stages of Cancer in France
2023 · C. Lachaize, F. Colrat, et al. · Value in Health
PDF
HTA5 Variation in Health Technology Assessments for Nivolumab Plus Chemotherapy Vs Chemotherapy in First-Line Gastric Cancer
2023 · D. Bertwistle, P. Casabianca, et al. · Value in Health
PDF
Épidémiologie, prise en charge et survie du cancer du poumon non à petites cellules de stade précoce traité par résection pulmonaire en France
2023 · C. Chouaid, P. Diez-Andreu, et al. · Revue des Maladies Respiratoires Actualités
P-152 Real-world data in patients with localized esophageal and gastro-esophageal junction cancer undergoing surgery in France: Results from the FREGAT database
2022 · G. Piessen, A. Adenis, et al. · Annals of Oncology
P-156 A European chart review of treatment patterns and outcomes for patients with resected esophageal cancer or gastroesophageal junction cancer
2021 · P. Singh, H. Xiao, et al. · Annals of Oncology
PDF
Works count: 14
Citation count: 13
H-index: 2
I10-index:
Year
Topic
Type